Liquid biopsy-based biomarkers for the characterization of hormone receptor-positive (HR+) HER2-Low metastatic breast cancer (mBC)

被引：0
|
作者：
Bortot, L. [1 ]
Basile, D. [2 ]
Palmero, L. [1 ]
Dri, A. [1 ]
Cucciniello, L. [1 ]
Buriolla, S. [1 ]
Pasto, B. [1 ]
Mazzeo, R. [1 ]
Bonotto, M. [3 ]
Bolzonello, S. [4 ]
Franzoni, A. [5 ]
Allegri, L. [5 ]
Belletti, B. [6 ]
Damante, G. [1 ]
Gerratana, L. [7 ]
Minisini, A. M. M. [3 ]
Puglisi, F. [8 ,9 ]
机构：
[1] Univ Udine, Dept Med DAME, Udine, Italy
[2] San Giovanni Dio Hosp, Med Oncol Unit, Crotone, Italy
[3] Azienda Sanitaria Univ Friuli Cent ASUFC, Santa Maria Misericordia Acad Hosp, Dept Oncol, Udine, Italy
[4] Ctr Riferimento Oncologico CRO, Dept Med Oncol, IRCCS, Aviano, Italy
[5] Azienda Sanitaria Univ Friuli Centrale ASUFC, Inst Human Genet, Udine, Italy
[6] Ctr Riferimento Oncol Aviano CRO, Mol Oncol Unit, IRCCS, Aviano, Italy
[7] Ctr Riferimento Oncol CRO, Dept Med Oncol, IRCCS, Aviano, Italy
[8] Univ Udine, Dept Med DAME, Udine, Italy
[9] Univ Udine, Dept Med DAME, Pordenone, Italy
来源：
ANNALS OF ONCOLOGY | 2022年 / 33卷 / 07期
关键词：
D O I：
10.1016/j.annonc.2022.07.300
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
261P
引用
收藏
页码：S656 / S657
页数：2
相关论文
共 50 条
  • [31] Lapatinib In Postmenopausal Women with Hormone Receptor-Positive, HER2-Positive Metastatic Breast Cancer
    Curran, Monique P.
    DRUGS, 2010, 70 (11) : 1411 - 1422
  • [32] Exploratory biomarkers in MONARCH 1, a phase II study of abemaciclib monotherapy in hormone-receptor positive (HR) HER2-metastatic breast cancer (MBC)
    Tolaney, S. M.
    Cortes, J.
    Dickler, M. N.
    Zamora, E.
    Caldwell, C. W.
    Nguyen, T. S.
    Nanda, S.
    Koustenis, A.
    Rugo, H. S.
    ANNALS OF ONCOLOGY, 2016, 27
  • [33] Outcomes with CDK4/6 inhibitors based on endocrine sensitivity in hormone receptor-positive metastatic breast cancer (HR plus MBC).
    Jain, Amit L.
    Mullins, Janice Nhan
    Poorman, Kelsey Anne
    Chaudhry, Amina
    Ranganath, Harsha Avinash
    Miller, Emily McCollum
    Valasareddy, Poojitha
    Smith, Justin R.
    Ryder, Julie
    Winerip, Michelle
    Schwartzberg, Lee S.
    Vidal, Gregory A.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [34] Saci-IO HR plus : Randomized phase II trial of sacituzumab govitecan (SG) plus /- pembrolizumab in PD-L1+hormone receptor-positive (HR+) / HER2-metastatic breast cancer (MBC).
    Garrido-Castro, Ana Christina
    Keenan, Tanya Elizabeth
    Li, Tianyu
    Lange, Paulina
    Callahan, Catherine
    Guerriero, Jennifer
    Tayob, Nabihah
    Anderson, Leilani
    Stover, Daniel G.
    Gogineni, Keerthi
    Carey, Lisa A.
    Nanda, Rita
    Winer, Eric P.
    Mittendorf, Elizabeth A.
    Tolaney, Sara M.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [35] Metastatic patterns and outcomes by HER2 and hormone receptor (HR) status in patients (pts) with metastatic breast cancer (mBC)
    Yuan, Qianyu
    Castellanos, Emily
    Fidyk, Erin
    Schwed, Karen
    Estevez, Melissa
    Nemeth, Sheila
    Linzmayer, Robin
    Cohen, Aaron B.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [36] Prognostic impact of HER2-low expression in hormone receptor positive early breast cancer
    Mutai, Raz
    Barkan, Tamar
    Moore, Assaf
    Sarfaty, Michal
    Shochat, Tzippy
    Yerushalmi, Rinat
    Stemmer, Salomon M.
    Goldvaser, Hadar
    BREAST, 2021, 60 : 62 - 69
  • [37] Abemaciclib after prior palbociclib exposure in patients with metastatic hormone-receptor positive (HR+)/HER2-breast cancer
    Wander, S. A.
    Spring, L. M.
    Stein, C. R.
    Yuen, M.
    Zangardi, M.
    O'Shaughnessy, J.
    Bardia, A.
    CANCER RESEARCH, 2019, 79 (04)
  • [38] Landscape of HER2-low metastatic breast cancer (MBC): Results from the AGMT-MBC-Registry
    Gampenrieder, Simon Peter
    Rinnerthaler, Gabriel
    Petzer, Andreas
    Tinchon, Christoph
    Fuchs, David
    Balic, Marija
    Heibl, Sonja
    Rumpold, Holger
    Egle, Daniel
    Zabernigg, August Felix
    Singer, Christian Fridolin
    Andel, Johannes
    Hubalek, Michael
    Knauer, Michael
    Greil, Richard
    CANCER RESEARCH, 2020, 80 (04)
  • [39] Hormone receptor-positive, HER2-negative metastatic breast cancer: redrawing the lines
    Matutino, A.
    Joy, A. A.
    Brezden-Masley, C.
    Chia, S.
    Verma, S.
    CURRENT ONCOLOGY, 2018, 25 : S131 - S141
  • [40] SYSTEMATIC REVIEW OF LAPATINIB PLUS LETROZOLE WITH OTHER FIRST LINE TREATMENTS FOR HORMONE POSITIVE (HR+) HER2+ADVANCED OR METASTATIC BREAST CANCER (MBC)
    Riemsma, R.
    Forbes, C. A.
    Amonkar, M.
    Lykopoulos, K.
    Diaz, J. R.
    Kleijnen, J.
    Rea, D. W.
    VALUE IN HEALTH, 2010, 13 (07) : A253 - A253
12345